Biggest News Aggregation in the World
📰 Aktx News

Page 3 - Aktx News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Aktx. Real-time updates on events, politics, business and more.

Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com

StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report released on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance NASDAQ:AKTX opened at $0.16 on Friday. The stock has a 50-day simple moving average of $0.18 and a two-hundred day simple […]
Renaissance Technologies Akari Therapeutics Plc Sabby Management Zakari Therapeutics Free Report Akari Therapeutics Daily

StockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)

StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a research note issued to investors on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Trading Up 0.6 % Shares of NASDAQ:AKTX opened at $0.16 on Thursday. Akari Therapeutics has a 12-month low of $0.14 and […]
United Kingdom City Of Renaissance Technologies Armistice Capital Sabby Management Akari Therapeutics Plc

StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)

StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a report released on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance AKTX opened at $0.16 on Thursday. Akari Therapeutics has a 1-year low of $0.14 and a 1-year high of $1.61. The stock […]
United Kingdom City Of Akari Therapeutics Plc Sabby Management Akari Therapeutics Company Profile Renaissance Technologies

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a report issued on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Price Performance NASDAQ AKTX opened at $0.21 on Tuesday. Akari Therapeutics has a 52 week low of $0.14 and a 52 week high of […]
City Of United Kingdom Akari Therapeutics Plc Renaissance Technologies Sabby Management Akari Therapeutics Company Profile

StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)

StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a research report sent to investors on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance Akari Therapeutics stock opened at $0.21 on Tuesday. The company has a 50 day moving average price of $0.21 […]
United Kingdom City Of Akari Therapeutics Plc Sabby Management Armistice Capital Renaissance Technologies

Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Update

Akari Therapeutics, Plc (NASDAQ:AKTX – Get Rating) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totalling 111,800 shares, a decline of 62.3% from the April 15th total of 296,900 shares. Based on an average daily volume of 444,700 shares, the days-to-cover ratio is […]
United Kingdom City Of Akari Therapeutics Plc Renaissance Technologies Armistice Capital Zakari Therapeutics
Source: wkrb13.com

StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a report published on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance Shares of AKTX opened at $0.18 on Monday. The firm has a market cap of $13.10 million, a P/E ratio of -0.50 […]
City Of United Kingdom Exchange Commission Akari Therapeutics Plc Akari Therapeutics Company Profile Zakari Therapeutics

Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a research note released on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance Shares of NASDAQ:AKTX opened at $0.18 on Friday. The company has a market capitalization of $13.40 million, a PE ratio of […]
United Kingdom City Of Akari Therapeutics Plc Omnia Family Wealth Armistice Capital Akari Therapeutics Company Profile

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science